Amyotrophic Lateral Sclerosis: An Overview

AN OVERVIEW- AMYOTROPHIC LATERAL SCLEROSIS

Authors

  • Ravindranath Saudagar Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India
  • Lajri Garge Department of Pharmaceutical Quality Assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

Abstract

Amyotrophic Lateral Sclerosis is an adult-onset neurodegenerative disease that causes paralysis. Presently it is incurable and rapidly progressive with a survival of 4-5 years from onset. It is degeneration of upper and lower motor neurons which results in weakness and wasting of muscles in arms, legs, trunk and bulbar region. There are two types sporadic and familial amyotrophic lateral sclerosis. The age of onset of people with familial is widely reported as being about 10 years younger than for those with apparently sporadic amyotrophic lateral sclerosis. Epidemiological studies show a worldwide incidence of 2-3 per year per 100-000 population over age of 15 years. About 10% of individuals have a family history of amyotrophic lateral sclerosis. The cause is unknown. Genes linked to diseases have been identified including one (C9ORF72) that seems to be particulary important. Researchers are studying several causes of ALS like gene mutation, chemical imbalance, disorganized immune response and protein mishandling. Riluzole and Radicava were approved for the treatment by the Food and Drug administration. The diagnosis of ALS is devastating for patient and family members. People with ALS should be delivered with multidisciplinary team. The current hope is that stem cells of neural or extraneural origin might be modified in vitro to neurons that may migrate to the sites of motor neuron loss. The quality of life is important not just the duration of survival.

Keywords: Amyotrophic Lateral Sclerosis, Motor neuron diseases, Sporadic, Familial, Pathogenesis.                                                                                                                                                                                                                 

DOI

https://doi.org/10.22270/jddt.v9i3.2874

Author Biographies

Ravindranath Saudagar, Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

Lajri Garge, Department of Pharmaceutical Quality Assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

Department of Pharmaceutical Quality Assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

References

Gwinn K, Corriveav RA, Mitsumoto H, Bednarz K, Brown RH, et al., Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery, Plos One, 2007; 2(12):1254.

Calvo AC, Manzano R, Deise MF, Munoz MJ, Zaragoza P, Osta R, et al., Amyotrophic Lateral Sclerosis: A Focus on Diseases Progression, BioMed Research International, 2014; 1-12.

Talbat K, Motor Neuron Diseases, Postgraduation Medical Journal, 2002; 78:513-519.

Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al., Amyotrophic Lateral Sclerosis. Lancet 2011; 377:942-955.

Brown RH, Al-Chalab A, Amyotrophic Lateral Sclerosis, The New England Journal of Medicine, 2017; 377:162-172.

Mehta PR, Jones AR, Opie-Martins S, Shatunov A, Lacuangeli A, et al., Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bais, Journal of Neurology and Neurosurgery Psychiatry, 2018; O:1-4.

Chio A, Traynor BF, Lombardo F, et al., Prevalence of SODI mutations in Italian ALS population, Neurology, 2008; 70:533-537.

Morgan S, Orrell RW, Pathogenesis of amyotrophic lateral sclerosis, British Medical Bulletin, 2016; 119:87-89.

Lattante S, Rouleau GA, Kabashi E, TARDBP and FUS mutations associated with Amyotrophic lateral Sclerosis: Summary, Human Mutations, 2013; 34:812-826.

Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL, Amyotrophic Lateral Sclerosis: mechanisms and therapeutics in the epigenomic era, Nature Reviews Neurology, 2015; 57:1-14.

Ricci C, Marzocchi C, Battistini S, Micro RNAs as Biomarkers in Amyotrophic Lateral Sclerosis, Cells, 2018; 7:211-219.

Orrell RW, Motor Neuron Diseases: systematic reviews of treatment for ALS and SMS, British Medical Bulletin, 2010; 93:145-159.

Mclntosh J, Murrell M, All about amyotrophic lateral sclerosis, Medical News Today, 2019; 1-8.

Published

2019-05-15
Statistics
Abstract Display: 792
PDF Downloads: 735

How to Cite

1.
Saudagar R, Garge L. Amyotrophic Lateral Sclerosis: An Overview: AN OVERVIEW- AMYOTROPHIC LATERAL SCLEROSIS. J. Drug Delivery Ther. [Internet]. 2019 May 15 [cited 2026 Apr. 30];9(3):613-6. Available from: https://jddtonline.info/index.php/jddt/article/view/2874

How to Cite

1.
Saudagar R, Garge L. Amyotrophic Lateral Sclerosis: An Overview: AN OVERVIEW- AMYOTROPHIC LATERAL SCLEROSIS. J. Drug Delivery Ther. [Internet]. 2019 May 15 [cited 2026 Apr. 30];9(3):613-6. Available from: https://jddtonline.info/index.php/jddt/article/view/2874

Most read articles by the same author(s)

> >>